New York, March 11 – Scientists have discovered a chemical in the zebra fish brain that helps reveal how it regrows its retina, a finding that can potentially cure blindness in humans. The findings showed that the levels of GABA , a neurotransmitter, best known for its role of calming nervous activity — drop when the unique self repair process kicks in.
Category: Macular Degeneration
New research identifies signal that appears to trigger retinal regeneration in zebrafish
If you were a fish and your retina was damaged, it could repair itself and your vision would be restored in a few weeks. Sadly, human eyes don’t have this beneficial ability.
Assessing the impact of stress in age-related macular degeneration
… approaches-for example, “mindfulness” interventions-have led to improved outcomes in patients with various health conditions. Dr. Dougherty and colleagues also note that stress may be associated with increased inflammation and that AMD is an …
AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 03, 2017 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017 at 8:30am PT in Dana Point, Calif. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
Dry (Atrophic) Macular Degeneration Therapeutic and Drug Pipeline Review H2
PUNE, INDIA, February 17, 2017 / EINPresswire.com / — The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action , route of administration and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
New transparent Micro-ring device could measure biological activities at back of the eye
… it with patients. The team continues to improve the device with support from Northwestern, the National Institutes of Health, Argonne National Laboratory, and the National Science Foundation. As word spreads about the device, about a dozen …
TRACON Pharma Announces Top-Line Results From NCI-Sponsored Phase 2…
Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients Combination was associated with a non-significant increase in overall survival SAN DIEGO, Feb. 09, 2017 — TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma funded and conducted by the Clinical Therapy Evaluation Program of the National Cancer Institute .
Wills Eye expert discusses what patients need to know about Age-Related Macular Degeneration
Carl D. Regillo, MD Chief of the Wills Eye Hospital Retina Service discusses what patients need to know about Age-Related Macular Degeneration . “It’s very important for people to know they have AMD, because we do have some very effective treatments,” Dr. Regillo says.
Bausch + Lomb and Prevent Blindness Partner With #WhyEyeFight Campaign for AMD Awareness Month
February is National Age-related Macular Degeneration Awareness Month and Bausch + Lomb along with Prevent Blindness are partnering for a second year in a row on the #WhyEyeFight Campaign. This campaign urges patients to join the fight for their sight by spreading the word about eye health and AMD.
Japan OKs retinal cell transplant using others’ iPS cells
Japan’s Ministry of Health, Labor and Welfare on Wednesday approved transplant of retinal cells to treat patients using induced pluripotent stem cells derived from another person. According to Japan’s public broadcaster NHK, the the application was filed in October last year by Kobe City Medical Center General Hospital, the government-backed Riken institute in Kobe, Kyoto University and Osaka University.
Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
MENLO PARK, Calif., Jan. 18, 2017 — Adverum Biotechnologies, Inc. a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today its participation in the Phacilitate Cell & Gene Therapy World 2017 conference held January 17-20, 2017 in Miami, Florida.
Experimental Drug Shows Promise for Sight-Stealing Eye Condition
… and a leading cause of vision loss among people age 60 and older, according to the U.S. National Institutes of Health. The condition causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp …
A Closer Look at the Eye
Researchers at the University of Rochester Medical Center have developed a new imaging technique that could revolutionize how eye health and disease are assessed. The group is first to be able to make out individual cells at the back of the eye that are implicated in vision loss in diseases like glaucoma.
Apollo Endosurgery Shares Up 20% After Going Public With Reverse Merger
Austin, Texas-based Apollo focuses on less-invasive therapies for the treatment of obesity and gastrointestinal disorders. Its investors include affiliates of PTV Healthcare Capital, H.I.G. BioHealth Partners, Remeditex Ventures, Novo A/S and CPMG Inc. Apollo’s deal to merge with San Diego, Calif.-based Lpath, which develops lipidomic-based therapeutic antibodies, was first announced Sept.
Keeping your eyes healthy in 2017
It’s that time of year again and New Year resolutions are coming at you from every health corner. Here in RNIB Cymru we support people with sight loss, but our work also includes campaigns to help with preventing sight loss.
New bionic eye ops on the NHS
Five local blind patients will be among the first in the country to receive revolutionary bionic eye implants funded by the NHS. NHS England will provide funding for further testing of the Argus II, also known as the Bionic Eye, for 10 patients with Retinitis Pigmentosa , an inherited disease that causes blindness.